Screening for Chronic Kidney Disease in HIV-Infected Patients

Advances in Chronic Kidney Disease

Volumn 17, Issue 1, 2010, Pages 26-35

  Estrella, Michelle M ^a   Fine, Derek M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cystatin C; Estimated glomerular filtration rate; HIV infection; Modification of Diet in Renal Disease equation; Proteinuria

Indexed keywords

CYSTATIN C;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; GENETIC PREDISPOSITION; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNO DEFICIENCY VIRUS ASSOCIATED NEPHROPATHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SCREENING;

AIDS-ASSOCIATED NEPHROPATHY; HUMANS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC;

EID: 71249153446     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2009.07.014     Document Type: Review

References (91)

1. UNAIDS. Report on the global AIDS epidemic (2006), UNAIDS, Geneva
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2005. Centers for Disease Control and Prevention 17 (2006), U.S. Department of Health and Human Services, Atlanta
3. Seaberg E.C., Munoz A., Lu M., et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 19 (2005) 953-960
4. Chow D.C., Souza S.A., Chen R., et al. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 4 (2003) 414-416
5. Koster J.C., Remedi M.S., Qiu H., et al. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 52 (2003) 1695-1700
6. Brown T., Cole S.R., Li X., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 165 (2005) 1179-1184
7. Riddler S.A., Smit E., Cole S.R., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 289 (2003) 2978-2982
8. Periard D., Telenti A., Sudre P., et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100 (1999) 700-705
9. Grinspoon S., and Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352 (2005) 48-62
10. Schwartz E.J., Szczech L.A., Ross M.J., et al. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 16 (2005) 2412-2420
11. Khan S., Haragsim L., and Laszik Z.G. HIV-associated nephropathy. Adv Chronic Kidney Dis 13 (2006) 307-313
12. Eggers P.W., and Kimmel P.L. Is there an epidemic of HIV infection in the US ESRD program?. J Am Soc Nephrol 15 (2004) 2477-2485
13. Szczech L.A., Gupta S.K., Habash R., et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 66 (2004) 1145-1152
14. Gardner L.I., Holmberg S.D., Williamson J.M., et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 32 (2003) 203-209
15. Jones C.Y., Jones C.A., Wilson I.B., et al. Cystatin C and creatinine in an HIV cohort: The nutrition for healthy living study. Am J Kidney Dis 51 (2008) 914-924
16. Overton E.T., Nurutdinova D., Freeman J., et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med 10 (2009) 343-350
17. Fernando S.K., Finkelstein F.O., Moore B.A., et al. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci 355 (2008) 89-94
18. Estrella M.M., Fine D.M., Gallant J.E., et al. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 43 (2006) 377-380
19. Hammer S.M., Eron J.J., Reiss P., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300 (2008) 555-570
20. Szczech L.A., Hoover D.R., Feldman J.G., et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 39 (2004) 1199-1206
21. Choi A.I., Rodriguez R.A., Bacchetti P., et al. Lower rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease. Clin Infect Dis 45 (2007) 1633-1639
22. Gupta S.K., Mamlin B.W., Johnson C.S., et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 61 (2004) 1-6
23. Fine D.M., Perazella M.A., Lucas G.M., et al. Kidney biopsy in HIV: Beyond HIV-associated nephropathy. Am J Kidney Dis 51 (2008) 504-514
24. Sedor J.R. Tissue proteomics: A new investigative tool for renal biopsy analysis. Kidney Int 75 (2009) 876-879
25. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
26. Gupta S.K., Eustace J.A., Winston J.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40 (2005) 1559-1585
27. Bakir A.A., and Dunea G. Drugs of abuse and renal disease. Curr Opin Nephrol Hypertens 5 (1996) 122-126
28. Fine D.M., Garg N., Haas M., et al. Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol 2 (2007) 1125-1130
29. Freedman B.I., Soucie J.M., Stone S.M., et al. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 34 (1999) 254-258
30. Appel G.B., Radhakrishnan J., Avram M.M., et al. Analysis of metabolic parameters as predicators of risk in the RENAAL study. Diabetes Care 26 (2003) 1402-1407
31. Ejerblad E., Fored C.M., Lindblad P., et al. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J Am Soc Nephrol 15 (2004) 2178-2185
32. Zimmermann A.E., Pizzoferrato T., Bedford J., et al. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 42 (2006) 283-290
33. Winston A., Amin J., Mallon P., et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med 7 (2006) 105-111
34. Moller C.C., Pollak M.R., and Reiser J. The genetic basis of human glomerular disease. Adv Chronic Kidney Dis 13 (2006) 166-173
35. Russo L.M., Sandoval R.M., McKee M., et al. The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: Retrieval is disrupted in nephrotic states. Kidney Int 71 (2007) 501-513
36. Kimmel P.L., Umana W.O., and Bosch J.P. Abnormal urinary protein excretion in HIV-infected patients. Clin Nephrol 39 (1993) 17-21
37. Busch H.W., Riechmann S., Heyen P., et al. Albuminuria in HIV-infected patients. AIDS Res Hum Retroviruses 10 (1994) 717-720
38. Zandi-Nejad K., Eddy A.A., Glassock R.J., et al. Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney Int Suppl 92 (2004) S76-S89
39. Siedner M.J., Atta M.G., Lucas G.M., et al. Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients. J Acquir Immune Defic Syndrom 47 (2008) 261-263
40. Ginsberg J.M., Chang B.S., Matarese R.A., et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 309 (1983) 1543-1546
41. Price C.P., Newall R.G., and Boyd J.C. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem 51 (2005) 1577-1586
42. Nguyen M.T., Maynard S.E., and Kimmel P.L. Misapplications of commonly used kidney equations: Renal physiology in practice. Clin J Am Soc Nephrol 4 (2009) 528-534
43. Gaspari F., Perico N., and Remuzz G. Measurement of glomerular filtration rate. Kidney Int Suppl 63 (1997) S151-S154
44. Levey A.S. Measurement of renal function in chronic renal disease (clinical conference). Kidney Int 38 (1990) 167-184
45. Verhave J.C., Fesler P., Ribstein J., et al. Estimation of renal function in subjects with normal serum creatinine levels: Influence of age and body mass index. Am J Kidney Dis 46 (2005) 233-241
46. Coresh J., Astor B.C., McQuillan G., et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39 (2002) 920-929
47. Ross J.W., Miller W.G., Myers G.L., et al. The accuracy of laboratory measurements in clinical chemistry: A study of 11 routine chemistry analytes in the College of American Pathologists Chemistry Survey with fresh frozen serum, definitive methods, and reference methods. Arch Pathol Lab Med 122 (1998) 587-608
48. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
49. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130 (1999) 461-470
50. Levey A.S., Greene T., Kusek J.W., et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (2000) 115A
51. Levey A.S., Coresh J., Greene T., et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53 (2007) 766-772
52. Coresh J., and Stevens L.A. Kidney function estimating equations: where do we stand?. Curr Opin Nephrol Hypertens 15 (2006) 276-284
53. Rule A.D., Larson T.S., Bergstralh E.J., et al. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med 141 (2004) 929-937
54. Bostom A.G., Kronenberg F., and Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 13 (2002) 2140-2144
55. Lin J., Knight E.L., Hogan M.L., et al. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14 (2003) 2573-2580
56. Levey A.S., Stevens L.A., Schmid C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009) 604-612
57. Roy M.T., First M.R., Myre S.A., et al. Effect of co-trimoxazole and sulfamethoxazole on serum creatinine in normal subjects. Ther Drug Monit 4 (1982) 77-79
58. Maia B.S., Engelson E.S., Wang J., et al. Antiretroviral therapy affects the composition of weight loss in HIV infection: Implications for clinical nutrition. Clin Nutr 24 (2005) 971-978
59. Huang E., Hewitt R.G., Shelton M., et al. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 16 (1996) 222-229
60. Noormohamed S.E., Katseres J.K., and Stapleton J.T. Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. Ren Fail 20 (1998) 627-633
61. Smith B.L., Sarnoski T.P., Dennis S., et al. Failure of predicted creatinine clearance equations in HIV-seropositive patients. Int J Clin Pharmacol Ther Toxicol 30 (1992) 394-399
62. Barraclough K., Er L., Ng F., et al. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract 111 (2009) c39-c48
63. Dharnidharka V.R., Kwon C., and Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. Am J Kidney Dis 40 (2002) 221-226
64. Laterza O.F., Price C.P., Scott M.G., and Cystatin C. An improved estimator of glomerular filtration rate?. Clin Chem 48 (2002) 699-707
65. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 38 suppl 1 (1992) S20-S27
66. Kottgen A., Selvin E., Stevens L.A., et al. Serum cystatin C in the United States: The Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 51 (2008) 385-394
67. Stevens L.A., Schmid C.H., Greene T., et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 75 (2009) 652-660
68. Knight E.L., Verhave J.C., Spiegelman D., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65 (2004) 1416-1421
69. Baxmann A.C., Ahmed M.S., Marques N.C., et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 3 (2008) 348-354
70. O'Riordan S.E., Webb M.C., Stowe J.H., et al. Cystatin C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 40 (2003) 648-655
71. Coll E., Botey A., Alvarez L., et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 36 (2000) 29-34
72. Christensson A.G., Grubb A., Nilsson J.A., et al. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but no severe diabetic nephropathy. J Intern Med 256 (2004) 510-518
73. Stevens L.A., Coresh J., Schmid C.H., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: A pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51 (2008) 395-406
74. Shlipak M.G., Katz R., Sarnak M.J., et al. Cystatin C and prognosis of cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145 (2006) 237-246
75. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
76. Larsson A., Helmersson J., Hansson L.O., et al. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest 65 (2005) 301-305
77. Odden M.C., Scherzer R., Bacchetti P., et al. Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: The FRAM study. Arch Intern Med 167 (2007) 2213-2219
78. Mocroft A., Wyatt C., Szczech L., et al. Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS 23 (2009) 71-82
79. El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
80. Nickolas T.L., Barasch J., and Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 17 (2008) 127-132
81. Yang J., Mori K., Li J.Y., and Barasch J. Iron, lipocalin, and kidney epithelia. Am J Physiol Renal Physiol 285 (2003) F9-F18
82. Bolignano D., Coppolino G., Campo S., et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 23 (2008) 414-416
83. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 4 (2009) 337-344
84. Soler-Garcia A.A., Johnson D., Hathout Y., et al. Iron-related proteins: candidate urine biomarkers in childhood HIV-associated renal diseases. Clin J Am Soc Nephrol 4 (2009) 763-771
85. Landro L., Damas J.K., Flo T.H., et al. Decreased serum lipocalin-2 levels inhuman immunodeficiency virus-infected patients: Increase during highly active anti-retroviral therapy. Clin Exp Immunol 152 (2008) 57-63
86. Borregaard N., Sehested M., Nielsen B.S., et al. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood 85 (1995) 812-917
87. Xu S., and Venge P. Lipocalins as biochemical markers of disease. Biochem Biophys Acta 1482 (2000) 298-307
88. Hemdahl A.L., Gabrielsen A., Zhu C., et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 26 (2006) 136-142
89. Ravani P., Tripepi G., Malberti F., et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 16 (2005) 2449-2455
90. Fliser D., Kronenberg F., Kielstein J.T., et al. Asymmetric dimetholarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 16 (2005) 2456-2461
91. Kamijo A., Sugaya T., Hikawa A., et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 284 (2006) 175-182